Education
About Us
Working with TipRanks
Follow Us
Diamedica Therapeutics Inc (DMAC)
NASDAQ:DMAC
Total Valuation
Diamedica Therapeutics has a market cap or net worth of $441.62M. The enterprise value is $285.91M.
Market Cap$441.62M
Enterprise Value$285.91M
Share Statistics
Diamedica Therapeutics has 52,077,440 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding52,077,440
Owned by Insiders45.52%
Owned by Institutions―
Financial Efficiency
Diamedica Therapeutics’s return on equity (ROE) is -0.60 and return on invested capital (ROIC) is -65.06%.
Return on Equity (ROE)-0.60
Return on Assets (ROA)-0.53
Return on Invested Capital (ROIC)-65.06%
Return on Capital Employed (ROCE)-0.65
Revenue Per Employee0.00
Profits Per Employee-905.33K
Employee Count27
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Diamedica Therapeutics is ―. Diamedica Therapeutics’s PEG ratio is 0.00.
PE Ratio―
PS Ratio0.00
PB Ratio5.39
Price to Fair Value5.39
Price to FCF-9.93
Price to Operating Cash Flow-12.23
PEG Ratio0.00
Income Statement
In the last 12 months, Diamedica Therapeutics had revenue of 0.00 and earned -24.44M in profits. Earnings per share was -0.60.
Revenue0.00
Gross Profit0.00
Operating Income-26.68M
Pretax Income-24.41M
Net Income-24.44M
EBITDA-26.64M
Earnings Per Share (EPS)-0.60
Cash Flow
In the last 12 months, operating cash flow was -27.79M and capital expenditures -41.19K, giving a free cash flow of -27.83M billion.
Operating Cash Flow-27.79M
Free Cash Flow-27.83M
Free Cash Flow per Share-0.53
Dividends & Yields
Diamedica Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.52
52-Week Price Change57.62%
50-Day Moving Average7.44
200-Day Moving Average5.48
Relative Strength Index (RSI)53.84
Average Volume (3m)559.91K
Important Dates
Diamedica Therapeutics upcoming earnings date is Mar 31, 2026, TBA (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 31, 2026
Ex-Dividend Date―
Financial Position
Diamedica Therapeutics as a current ratio of 8.28, with Debt / Equity ratio of 1.07%
Current Ratio8.28
Quick Ratio8.28
Debt to Market Cap0.00
Net Debt to EBITDA0.11
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Diamedica Therapeutics has paid 30.00K in taxes.
Income Tax30.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Diamedica Therapeutics EV to EBITDA ratio is -8.89, with an EV/FCF ratio of -9.81.
EV to Sales0.00
EV to EBITDA-8.89
EV to Free Cash Flow-9.81
EV to Operating Cash Flow-9.82
Balance Sheet
Diamedica Therapeutics has $55.32M in cash and marketable securities with $266.00K in debt, giving a net cash position of $55.05M billion.
Cash & Marketable Securities$55.32M
Total Debt$266.00K
Net Cash$55.05M
Net Cash Per Share$1.06
Tangible Book Value Per Share$1.01
Margins
Gross margin is 0.03%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.03%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Diamedica Therapeutics is $17.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$17.00
Price Target Upside100.47% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast-29.73%